14 terminated. 14 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 14 |
| Phase 3 | 3 | Terminated 3 |
| Phase 1 | 2 | Terminated 2 |
Follow Dwarfism: new trials by email Literature Review of Dwarfism trials Research Report on Dwarfism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) GS3-007a dry suspension, Insulin - Adult Growth Hormone Deficiency (AGHD) | Phase 2 | Terminated | Changchun GeneScience Pharmaceutical Co., Ltd. | 120 | 2025-12-19 | 2026-05-22 |
| Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia Recifercept - Achondroplasia | Phase 2 | Terminated | Pfizer | 35 | 2021-12-24 | 2024-02-08 |
| A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia Recifercept - Achondroplasia | Phase 2 | Terminated | Pfizer | 60 | 2020-12-02 | 2024-02-15 |
| Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD) somavaratan - Adult Growth Hormone Deficiency (AGHD) | Phase 2 | Terminated | Versartis Inc. | 36 | 2016-02-11 | 2023-04-13 |
| A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children TV-1106, somatropin - Growth Hormone-Deficiency | Phase 2 | Terminated | Teva Pharmaceutical Industries, Ltd. | 65 | 2014-04-30 | 2021-11-09 |
| Versartis Long-Term Safety Study of Somavaratan somavaratan - Pediatric Growth Hormone Deficiency | Phase 2 / Phase 3 | Terminated | Versartis Inc. | 385 | 2014-03-03 | 2018-03-09 |
| Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg - Obesity, Short Stature | Phase 1 / Phase 2 | Terminated | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 37 | 2011-07-01 | 2018-12-17 |
| Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly Growth Hormone Releasing Hormone (GHRH ) - Hormone Deficiency, Aging | Phase 2 | Terminated | University of Pennsylvania | 13 | 2011-05-01 | 2019-05-24 |
| Clinical Trial of Growth Hormone in MPS I, II, and VI Somatropin (DNA origin) - Mucopolysaccharidosis I, Mucopolysaccharidosis II | Phase 2 / Phase 3 | Terminated | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 2 | 2008-11-01 | 2018-09-05 |
| Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors Recombinant Human Growth Hormone, Recombinant Human IGF-1 - Growth Hormone Deficiency | Phase 1 / Phase 2 | Terminated | Columbia University | 5 | 2008-01-01 | 2024-07-17 |
| Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly GHRH - Elderly | Phase 2 | Terminated | Johns Hopkins University | 5 | 2007-12-17 | 2017-04-27 |
| Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease somatropin [rDNA origin] for injection - Arthritis, Juvenile Rheumatoid, Crohn Disease | Phase 2 / Phase 3 | Terminated | Nationwide Children's Hospital | 10 | 2007-08-01 | 2018-04-12 |
| A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency PHA-794428 - Growth Hormone Deficiency | Phase 2 | Terminated | Pfizer | 136 | 2006-07-01 | 2011-05-18 |
| A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency PHA-794428 - Growth Hormone Deficiency | Phase 2 | Terminated | Pfizer | 32 | 2006-04-01 | 2011-05-16 |
Dwarfism, Pituitary (10) · Achondroplasia (2) · Mucopolysaccharidosis IV (2) · Arthritis, Juvenile (1) · Bone Diseases (1) · Chronic Disease (1) · Crohn Disease (1) · Failure to Thrive (1) · Genetic Diseases, Inborn (1) · Growth Disorders (1) · Mucopolysaccharidosis I (1) · Mucopolysaccharidosis II (1) · Mucopolysaccharidosis VI (1) · Musculoskeletal Diseases (1)
Bone Diseases, Developmental (14) · Bone Diseases (13) · Endocrine System Diseases (13) · Musculoskeletal Diseases (13) · Nervous System Diseases (11) · Bone Diseases, Endocrine (10) · Brain Diseases (10) · Central Nervous System Diseases (10) · Hypopituitarism (10) · Hypothalamic Diseases (10) · Pituitary Diseases (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (5) · Connective Tissue Diseases (4)
Human Growth Hormone (3) · Growth Hormone (2) · Growth Hormone-Releasing Hormone (2) · Insulin (1) · WW Domain-Containing Oxidoreductase (1) · albusomatropin (1)
Pfizer (4) · Versartis Inc. (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Columbia University (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Johns Hopkins University (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Nationwide Children's Hospital (1) · Teva Pharmaceutical Industries, Ltd. (1) · University of Pennsylvania (1)
United States (8) · Belgium (4) · Spain (4) · Denmark (3) · Italy (3) · Australia (2) · France (2) · Germany (2) · Israel (2) · Poland (2) · Portugal (2) · United Kingdom (2) · Belarus (1) · Bulgaria (1) · China (1)
Dariush Elahi, PhD (2) · Will Charlton, MD (2) · Dana S Hardin, MD (1) · Jack A Yanovski, M.D. (1) · Kenneth L. Minaker, MD (1) · Lynda E Polgreen, M.D. (1) · Pamela U. Freda, M.D. (1)
P01AG000599 (1)